Through our supplementary analyses of differential splicing patterns of SPP1 and its interacting oncogenes, we add an additional layer of detail to previous findings by confirming the variations in functionality that occur in conjunction with oncogenic overexpression in conditions conducive to cancer progression or in response to treatment methods imparted, thereby further validating SPP1 to be a biomarker as well as a potential therapeutic target in the types of cancer studied [17,18]. The gene discussed is SPP1; the disease is cancer.